

# Appendix 3Y

## Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b>	<b>The Hydration Pharmaceuticals Company Limited</b>
<b>ACN</b>	<b>620 385 677</b>

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Margaret Hardin
<b>Date of last notice</b>	9 March 2023

### Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Indirect
<b>Nature of indirect interest (including registered holder)</b> Note: Provide details of the circumstances giving rise to the relevant interest.	Margaret L Hardin as trustee for Margaret L Hardin Revocable 2013 Trust  (Margaret Hardin has the power to exercise, or control the exercise of, a right to vote attached to the securities and to dispose of, or control the exercise of a power to dispose of, the securities.)
<b>Date of change</b>	2 October 2023
<b>No. of securities held prior to change</b>  Margaret L Hardin  Margaret L Hardin as trustee for Margaret L Hardin Revocable 2013 Trust*  *(Margaret Hardin has the power to exercise, or control the exercise of, a right to vote attached to the securities and to dispose of, or control the exercise of a power to dispose of, the securities.)	53,571 unlisted options issued under the EIP exercisable at \$0.476 per option and expiring on 22 July 2027  39,130 Fully Paid Ordinary Shares
<b>Class</b>	1. Fully Paid Ordinary Shares 2. Unlisted Options

+ See chapter 19 for defined terms.

## Appendix 3Y

### Change of Director's Interest Notice

<b>Number acquired</b>	<ol style="list-style-type: none"> <li>333,333 Fully Paid Ordinary Shares</li> <li>166,667 Unlisted Options</li> </ol>
<b>Number disposed</b>	Nil
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and estimated valuation	<ol style="list-style-type: none"> <li>\$0.045 per fully paid ordinary share subscribed for as sub-underwriter under the Company's Entitlement Offer.</li> <li>Nil consideration – one attaching option for every two shares subscribed for as sub-underwriter under the Company's Entitlement Offer.</li> </ol>
<b>No. of securities held after change</b>  Margaret L Hardin  Margaret L Hardin as trustee for Margaret L Hardin Revocable 2013 Trust*  *(Margaret Hardin has the power to exercise, or control the exercise of, a right to vote attached to the securities and to dispose of, or control the exercise of a power to dispose of, the securities.)	53,571 unlisted options issued under the EIP exercisable at \$0.476 per option and expiring on 22 July 2027  372,463 Fully Paid Ordinary Shares  166,667 unlisted options exercisable at \$0.07 per option and expiring on 31 December 2025.
<b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Participation in the pro rata, non-renounceable entitlement offer announced to the market on 3 August 2023 in the capacity as sub-underwriter. See prospectus dated 4 August 2023 and amended Appendix 3B dated 30 August 2023 for further details.

## Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	
<b>Name of registered holder (if issued securities)</b>	
<b>Date of change</b>	

+ See chapter 19 for defined terms.

<b>No. and class of securities to which interest related prior to change</b> <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	
<b>Interest acquired</b>	
<b>Interest disposed</b>	
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	
<b>Interest after change</b>	

**Part 3 – <sup>+</sup>Closed period**

<b>Were the interests in the securities or contracts detailed above traded during a <sup>+</sup>closed period where prior written clearance was required?</b>	No
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	
<b>If prior written clearance was provided, on what date was this provided?</b>	

---

<sup>+</sup> See chapter 19 for defined terms.

# Appendix 3Y

## Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b>	<b>The Hydration Pharmaceuticals Company Limited</b>
<b>ACN</b>	<b>620 385 677</b>

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Adem Karafili
<b>Date of last notice</b>	14 June 2023

### Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Indirect
<b>Nature of indirect interest (including registered holder)</b> Note: Provide details of the circumstances giving rise to the relevant interest.	Ankara Holdings Pty Ltd <The Ankara Family Trust>  (Adem Karafili has the power to exercise, or control the exercise of, a right to vote attached to the securities and to dispose of, or control the exercise of a power to dispose of, the securities.)
<b>Date of change</b>	1. 2 October 2023 2. 2 October 2023 3. 8 August 2023
<b>No. of securities held prior to change</b>  Ankara Holdings Pty Ltd <The Ankara Family Trust>*	907,289 fully paid ordinary shares  653,128 fully paid ordinary shares subject to escrow until 13/12/2023  74,739 unlisted options with an exercise price of \$0.45 expiring on 13 January 2029 subject to escrow until 13/12/23

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

<p>Ankara Holdings Pty Ltd ATF A&amp;N Karafili Family Trust*</p> <p>*Adem Karafili has the power to exercise, or control the exercise of, a right to vote attached to the securities and to dispose of, or control the exercise of a power to dispose of, the securities.</p>	<p>The following unlisted options to acquire ordinary shares, all of which are subject to ASX escrow until 9 December 2023:</p> <ul style="list-style-type: none"> <li>• 100,000 unlisted options with an exercise price of \$0.29 expiring on 31 August 2024;</li> <li>• 800,000 unlisted options with an exercise price of \$0.20 expiring on 31 August 2024; and</li> <li>• 1,000,000 unlisted options with an exercise price of \$0.29 expiring on 1 December 2026.</li> </ul> <p>53,571 unlisted options issued under the EIP exercisable at \$0.476 per option and expiring on 22 July 2027</p>
<p><b>Class</b></p>	<ol style="list-style-type: none"> <li>1. Fully Paid Ordinary Shares</li> <li>2. Unlisted Options</li> <li>3. Fully Paid Ordinary Shares</li> </ol>
<p><b>Number acquired</b></p>	<ol style="list-style-type: none"> <li>1. 1,000,000 Fully Paid Ordinary Shares</li> <li>2. 500,000 Unlisted Options</li> <li>3. 1,972 Fully Paid Ordinary Shares, all of which are escrowed until 13 December 2023</li> </ol>
<p><b>Number disposed</b></p>	<p>Nil</p>
<p><b>Value/Consideration</b>  Note: If consideration is non-cash, provide details and estimated valuation</p>	<ol style="list-style-type: none"> <li>1. \$0.045 per fully paid ordinary share subscribed for as sub-underwriter under the Company's Entitlement Offer</li> <li>2. Nil consideration - one attaching option for every two shares subscribed for as sub-underwriter under the Company's Entitlement Offer</li> <li>3. \$0.2146 per fully paid ordinary share</li> </ol>
<p><b>No. of securities held after change</b></p> <p>Ankara Holdings Pty Ltd &lt;The Ankara Family Trust&gt;*</p>	<p>1,907,289 fully paid ordinary shares</p> <p>655,100 fully paid ordinary shares subject to escrow until 13/12/2023</p> <p>74,739 unlisted options with an exercise price of \$0.45 expiring on 13 January 2029 subject</p>

+ See chapter 19 for defined terms.

## Appendix 3Y Change of Director's Interest Notice

<p>Ankara Holdings Pty Ltd ATF A&amp;N Karafili Family Trust*</p> <p>*Adem Karafili has the power to exercise, or control the exercise of, a right to vote attached to the securities and to dispose of, or control the exercise of a power to dispose of, the securities.</p>	<p>to escrow until 13/12/23</p> <p>500,000 unlisted options exercisable at \$0.07 per option and expiring on 31 December 2025.</p> <p>The following unlisted options to acquire ordinary shares, all of which are subject to ASX escrow until 9 December 2023:</p> <ul style="list-style-type: none"> <li>• 100,000 unlisted options with an exercise price of \$0.29 expiring on 31 August 2024;</li> <li>• 800,000 unlisted options with an exercise price of \$0.20 expiring on 31 August 2024; and</li> <li>• 1,000,000 unlisted options with an exercise price of \$0.29 expiring on 1 December 2026.</li> </ul> <p>53,571 unlisted options issued under the EIP exercisable at \$0.476 per option and expiring on 22 July 2027</p>
<p><b>Nature of change</b></p> <p>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</p>	<ol style="list-style-type: none"> <li>1. Participation in the pro rata, non-renounceable entitlement offer announced to the market on 3 August 2023 in the capacity as sub-underwriter. See prospectus dated 4 August 2023 and amended Appendix 3B dated 30 August 2023 for further details.</li> <li>2. Participation in the pro rata, non-renounceable entitlement offer announced to the market on 3 August 2023 in the capacity as sub-underwriter. See prospectus dated 4 August 2023 and amended Appendix 3B dated 30 August 2023 for further details.</li> <li>3. Issue of shares subject to mandatory escrow on rectification of conversion of pre-IPO convertible notes as announced to ASX on 9 August 2023.</li> </ol>

### Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

---

+ See chapter 19 for defined terms.

Appendix 3Y  
Change of Director's Interest Notice

---

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	
<b>Name of registered holder (if issued securities)</b>	
<b>Date of change</b>	
<b>No. and class of securities to which interest related prior to change</b> <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	
<b>Interest acquired</b>	
<b>Interest disposed</b>	
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	
<b>Interest after change</b>	

**Part 3 – <sup>+</sup>Closed period**

<b>Were the interests in the securities or contracts detailed above traded during a <sup>+</sup>closed period where prior written clearance was required?</b>	No
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	
<b>If prior written clearance was provided, on what date was this provided?</b>	

---

<sup>+</sup> See chapter 19 for defined terms.